Asia-Pacific Cancer Immunotherapy Market Size was valued at USD 114.1 Billion in 2023. The Asia-Pacific Cancer Immunotherapy market industry is projected to grow from USD 130.18 Billion in 2024 to USD 327.77 Billion by 2032, exhibiting a growth rate or CAGR (compound annual growth rate) of 12.23% during the projected timeframe (2024 - 2032). The rising cancer population results from the changing environment and rising government funding for development and research are the key market drivers contributing to market growth and expansion.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The rising cancer population because of the changing environment drives the market CAGR for Asia-Pacific Cancer Immunotherapy. The growing frequency of Cancer in the population and the rising number of cancer-related fatalities drive the worldwide cancer immunotherapy market. Furthermore, traditional chemotherapy had drawbacks such as organ failure and cancer recurrence, which drove patients to adopt innovative cancer immunotherapy. Furthermore, technical improvements and medication discovery have fueled the expansion of the industry. Cancer immunotherapy instructs the body's immune system to attack and eliminate cancer-affected cells. This medicine has fewer adverse and long-term treatment effects, increasing the popularity of cancer immunotherapy worldwide. The increasing number of cancer patients has fueled the market's expansion. Increasing knowledge of cancer immunotherapy and its benefits, technical improvement, quick acceptance, and rising demand from emerging nations are driving market expansion.
Additionally, the growing use of combination medicines for the treatment of Cancer is projected to drive up demand for immunotherapy. Combination treatments target several pathways inside the tumor microenvironment, potentially increasing the immunotherapeutic treatment's efficacy. Companies are primarily focusing on developing targeted medicines as innovative regimens for treating cancer disorders. Furthermore, the discovery and approval of innovative immunotherapy therapies for relapsed and refractory cancers is hastening the growth of the cancer immunotherapy market. The government has improved oversight of the use of immunology. It is also in charge of clinical studies that follow official guidelines, making it harder for firms to enter the field and, as a result, predicted to hinder market development.
The COVID-19 epidemic has severely impacted hospital purchasing capabilities, particularly at small-scale clinics and scanning centers. According to a Cigna article, hospitalizations for non-elective diseases, like as a result of acute coronary syndrome and transient ischemic episodes, have decreased, raising the idea that patients are procrastinating critical clinical care. Clinical trials of novel cancer immunotherapy medications have been halted since individuals are more vulnerable to COVID-19 during this crisis. COVID-friendly cancer therapy, on the other hand, has been shown to increase with time and will continue to grow in the years to come. As a result, the COVID-19 pandemic is expected to harm the cancer immunotherapy business.
For instance, according to the IAR Report Against Cancer, there will be around 19.3M cancer cases and 10M deaths worldwide in 2020. Worldwide cases are expected to rise by 47% between 2020 and 2040. An increase in cancer immunotherapy awareness programs will help the sector gain momentum during the forecast time frame. Thus, demand for Asia-Pacific Cancer Immunotherapy is anticipated to increase throughout the projected timeframe due to the rising building and construction industries. Thus, driving the Asia-Pacific Cancer Immunotherapy market revenue.
The Asia-Pacific Cancer Immunotherapy market segmentation, based on Type, includes Monoclonal Antibodies, Cancer Vaccines, and Immunomodulators. The monoclonal antibodies category dominated the market, accounting for 42% of market revenue (USD 42 Billion) in 2022. Monoclonal antibodies effectively identify specific cancer-affected tissues and treat them without damaging normal cells. As a result, it is regarded safer and has lower toxicity than chemotherapy.
Figure 1: Asia-Pacific Cancer Immunotherapy Market, by Type, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Asia-Pacific Cancer Immunotherapy market segmentation, based on Applications, includes Lung Cancer, Blood Cancer, Melanoma, and Breast Cancer. The lung cancer category generated the highest market revenue of about 38% (USD 38 billion) in 2022. This is simply due to an increase in the prevalence of lung cancer in the worldwide population. Lung cancer was responsible for around 1.8 million fatalities in 2020. It is responsible for 18% of all cancer deaths worldwide.
The Asia-Pacific Cancer Immunotherapy market segmentation, based on End-Use, includes Hospitals, Research Laboratories, and Cancer Institutes. The hospitals category dominated the market, accounting for 46% of market revenue (USD 46 Billion) in 2022. This can be ascribed to increased hospital admissions connected to cancer therapy. Furthermore, the rising number of public and private medical centers worldwide is the primary choice of individuals seeking treatment for various forms of Cancer.
By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The China Cancer Immunotherapy market will dominate during the projected timeframe, owing to the increasing incidence of malignancies, the expanding emphasis on the development and research of effective cancer medicines, and an increasing amount of new product approvals and launches, as well as increased investment, are the primary drivers driving market expansion in China.
Furthermore, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Asia-Pacific Cancer Immunotherapy Market Share by Region 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Japan region’s Cancer Immunotherapy market accounts for the second-highest market share due to the availability of highly qualified medical personnel, rising demand for treatment, and strong acceptance of these medicines are all driving the cancer immunotherapy industry in Japan.
The India Cancer Immunotherapy Marketis expected to grow quickly during the projected timeframe. With rising government backing for research and development, India has become the region's biggest consumer of cancer immunotherapy. Rising government efforts and support and rising healthcare expenditures due to the country's strengthening economy boost the cancer immunotherapy industry.
Asia-Pacific Cancer Immunotherapy Key Market Players & Competitive Insights
Leading market players invested heavily in research and Development (R&D) to scale up their manufacturing units and develop technologically advanced solutions, which will help the Asia-Pacific Cancer Immunotherapy market grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their global footprint, with significant market developments including new Type portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings. The Asia-Pacific Cancer Immunotherapy industry must offer cost-effective and sustainable options to survive in a highly fragmented and dynamic market climate.
Manufacturing locally to minimize operational expenses and offer aftermarket services to customers is one of the critical business strategies organizations use in the Asia-Pacific Cancer Immunotherapy industry to benefit customers and capture untapped market share and revenue. The Asia-Pacific Cancer Immunotherapy industry has recently offered the Advanced Materials industry significant advantages. Moreover, more industry participants are utilizing and adopting cutting-edge technology has grown substantially. Major players in the Asia-Pacific Cancer Immunotherapy market, including Amgen, Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), and AstraZeneca Plc. (UK), GlaxoSmithKline Plc. (UK), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (US), Janssen Biotech Inc. (US), Sanofi (France), AbbVie Inc. (US), Takeda Pharmaceuticals (Japan), Oncomed Pharmaceuticals (US) and Immunomedics (US) are attempting to expand market share and demand by investing in R&D operations to produce sustainable and affordable solutions.
Roche has become one of the biggest worldwide biotech firms, an established manufacturer of in-vitro tests, and a global developer of transformational new solutions in significant disease areas. Roche Holding AG is a healthcare research firm. It works in two categories: diagnostics and pharma. In May 2022, Roche Pharma launched PHESGO, which was the initial fixed-dose oncology creation that combines a pair of monoclonal antibodies, Perjeta along with Herceptin, with hyaluronidase, given by injection under the skin alongside intravenous chemotherapy, for the therapy of early-stage and metastatic HER2-positive breast cancer.
AstraZeneca Plc is a pharmaceutical holding company that conducts research, development, and manufacturing. Its pipeline is utilized for Cancer, cardiovascular, renal, metabolic, and respiratory therapies. The firm was created on June 17, 1992, and is based in Cambridge, England. In July 2018, they said its immunotherapy medication Imfinzi had won regulatory clearance in Japan for novel applications of two major cancer treatments.
Key Companies in the Asia-Pacific Cancer Immunotherapy market include
AmgenInc. (US)
Bristol-Myers Squibb Company (US)
Eli Lilly and Company (US)
AstraZeneca Plc. (UK)
GlaxoSmithKline Plc. (UK)
Bayer AG (Germany)
F. Hoffmann-La Roche Ltd. (Switzerland)
PfizerInc. (US)
Asia-Pacific Cancer Immunotherapy Industry Developments
February 2022:Roche Pharma launched PHESGO, which was the initial fixed-dose oncology creation that combines a pair of monoclonal antibodies, Perjeta along with Herceptin, with hyaluronidase, given by injection under the skin alongside intravenous chemotherapy, for the therapy of early-stage and metastatic HER2-positive breast cancer.
February 2022:Opdivo (nivolumab) Intravenous Infusion ("Opdivo"), a humanized anti-human PD-1 monoclonal antibody, obtained approval from the MFD in South Korea in February for two adjuvant therapies and three combination treatments for various cancers.
July 2018:AstraZeneca Plc. (UK), a global pharmaceutical and biopharmaceutical firm said that its immunotherapy medication Imfinzi had won regulatory clearance in Japan for novel applications of two major cancer treatments.
Monoclonal Antibodies
Cancer Vaccines
Immunomodulators
Lung Cancer
Blood Cancer
Melanoma
Breast Cancer
Hospital
Research Laboratories
Cancer Institute
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 114.1 Billion |
| Market Size 2024 | USD 130.18 Billion |
| Market Size 2032 | USD 327.77 Billion |
| Compound Annual Growth Rate (CAGR) | 12.23% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, End-Use, and Region |
| Geographies Covered | Asia Pacific |
| Countries Covered | China, Japan, India, Australia, South Korea, Rest of Asia-Pacific |
| Key Companies Profiled | Amgen, Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), AstraZeneca Plc. (UK), GlaxoSmithKline Plc. (UK), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (US), Janssen Biotech Inc. (US), Sanofi (France), AbbVie Inc. (US), Takeda Pharmaceuticals (Japan), Oncomed Pharmaceuticals (US) and Immunomedics (US) |
| Key Market Opportunities | Rising government funding for development and research Growing healthcare spending |
| Key Market Dynamics | The rising cancer population is a result of changing environment. |
Asia Pacific Cancer Immunotherapy Market Highlights:
Frequently Asked Questions (FAQ) :
The Asia-Pacific Cancer Immunotherapy market size was valued at USD 114.1 Billion in 2023.
The Asia-Pacific Cancer Immunotherapy market is estimated to grow and expand at a CAGR of 12.23% during the projected timeframe.
The key players in the Asia-Pacific Cancer Immunotherapy Market are Amgen, Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), and AstraZeneca Plc. (UK), GlaxoSmithKline Plc. (UK), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (US), Janssen Biotech Inc. (US), Sanofi (France), AbbVie Inc. (US), Takeda Pharmaceuticals (Japan), Oncomed Pharmaceuticals (US) and Immunomedics (US).
The Monoclonal Antibodies category dominated the market in 2022.
Lung Cancer had the largest share of the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
